EUCOPE Resources / News / Press Releases - July 29, 2021
The European Commission is consulting stakeholders as part of its revision process of two major pieces of legislation, on medicines for rare diseases and paediatric patients. Central to the development of innovative treatments for these specific categories of patients, this revision process represents an important… read more
News / Press Releases - June 11, 2021
The multidisciplinary European Expert Group on Orphan Drug Incentives (OD Expert Group) has developed fourteen innovative proposals along the entire lifecycle of orphan drug development to address the unmet needs in rare diseases. With over ninety percent of patients without a centrally approved treatment option,… read more
News / Press Releases - April 29, 2021
The COVID-19 pandemic has again made the vital importance of the European pharmaceutical sector apparent, and while regulatory simplification is welcomed, broader business incentives should also be considered to address the EU’s competitiveness. In its response to the EU roadmap/IIA on the “Evaluation and revision of… read more
Press Releases - March 16, 2021
EUCOPE welcomes the important collaborative effort made today 16 March by the Council of the EU to reach a compromise on the EU on a Proposal for a Regulation on health technology assessment (HTA) and amending Directive 2011/24/EU. The Portuguese Presidency underscored the difficulty of… read more
News / Press Releases - March 3, 2021
A large consortium of European health-related stakeholders, including industry players, academia, healthcare professionals and patients, share their satisfaction on the draft adequacy decision on the UK data protection regime issued by the European Commission on 19th February 2021. Protecting the benefits of the free flow… read more
EUCOPE Resources / Press Releases - January 7, 2021
EUCOPE, the European association for small to medium-sized companies active in pharmaceuticals and biotechnologies submitted its response to the Paediatric and Orphan Medicinal Products (OMPs) inception impact assessment. EUCOPE represents 130 companies, many focused on rare diseases, largely small to medium-sized, playing a key role… read more
EUCOPE Resources / News / Press Releases - November 25, 2020
EUCOPE, the European association for small to medium-sized companies active in pharmaceuticals and biotechnologies – many of which are researching and developing rare disease treatments – notes the publication of the European Commission Communication on the Pharmaceutical Strategy for Europe. EUCOPE calls for a comprehensive Pharmaceutical Strategy… read more
Press Releases - August 11, 2020
Brussels 11 August 2020 – EUCOPE, the European association for small to medium-sized companies in the field of pharmaceuticals, biotechnologies – many of which are researching and developing rare disease treatments – notes the publication of the evaluation of EU legislation on Orphan Medicinal Products… read more
Press Releases - August 11, 2020
EUCOPE, the European association for small to medium-sized companies in the field of pharmaceuticals, biotechnologies – many of which are researching and developing rare disease treatments – notes the publication of the study on the EU Regulation 141/2000 on Orphan Medicinal Products (OMPs) (here below)…. read more
News / Press Releases - July 7, 2020
On the verge of the publication of the EU industrial strategy in March, EUCOPE shared the expectations and ambitions of its membership for a coherent strategy that harness Europe’s untapped potential: small and medium biopharma. The mission letter from President von der Leyen to Commissioner Kyriakides… read more
